Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

被引：7
|
作者：
Jerkeman, Mats
Kolstad, Arne
Niemann, Carsten Utoft
Groenbaek, Kirsten
Hutchings, Martin
Pasanen, Annika
Ekberg, Sara
Wader, Karin Fahl
Glimelius, Ingrid
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
    Jerkeman, Mats
    Kolstad, Arne
    Hutchings, Martin
    Pasanen, Annika
    Meriranta, Leo
    Niemann, Carsten Utoft
    Jorgensen, Rasmus Rask Kragh
    El-Galaly, Tarec Christoffer Christoffer
    Riise, Jon
    Leppa, Sirpa
    Christensen, Jacob Haaber
    Wader, Karin Fahl
    Glimelius, Ingrid
    BLOOD, 2022, 140
  • [2] Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
    Jerkeman, Mats
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Christensen, Jacob H.
    Kuitunen, Hanne
    Eskelund, Christian Winther
    Groenbaek, Kirsten
    Niemann, Carsten Utoft
    Geisler, Christian H.
    Kolstad, Arne
    BLOOD, 2020, 136
  • [3] Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
    Jerkeman, Mats
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Kuitunen, Hanne
    Toldbod, Helle
    Pedersen, Lone Bredo
    Eskelund, Christian Winther
    Gronbaek, Kirsten
    Niemann, Carsten Utoft
    Geisler, Christian H.
    Kolstad, Arne
    BLOOD, 2016, 128 (22)
  • [4] MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
    Jerkeman, Mats
    Kolstad, Arne
    Hutchings, Martin
    Pasanen, Annika
    Meriranta, Leo
    Niemann, Carsten Utoft
    Jorgensen, Rasmus Rask Kragh
    El-Galaly, Tarec Christoffer
    Riise, Jon
    Leppa, Sirpa
    Christensen, Jacob Haaber
    Sonnevi, Kristina
    Pedersen, Lone Bredo
    Wader, Karin Fahl
    Glimelius, Ingrid
    BLOOD ADVANCES, 2024, 8 (02) : 407 - 415
  • [5] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [6] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Luhua
    Fayad, Luis
    Hagemeister, Fredrick B.
    Neelapu, Sattva
    Samaniego, Felipe
    McLaughlin, Peter
    Samuels, Barry
    Yi, Qing
    Pro, Barbara
    Fanale, Michelle
    Shah, Jatin
    Younes, Anas
    Bell, Neda
    Knight, Robert
    Zeldis, Jerome B.
    Cabanillas, Fernando
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2009, 114 (22) : 1064 - 1065
  • [7] Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial
    Forsgren, Elin
    Jorgensen, Rasmus R. K.
    Bentzen, Hans
    Riise, Jon
    Haaber, Jacob
    Pasanen, Annika
    Kuitunen, Hanne
    Wader, Karin F.
    El-Galaly, Tarec C.
    Hutchings, Martin
    Glimelius, Ingrid
    Jerkeman, Mats
    HEMASPHERE, 2025, 9 (03):
  • [8] MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial ( vol 8, pg 407, 2024)
    Jerkeman, M.
    Kolstad, A.
    Hutchings, M.
    BLOOD ADVANCES, 2024, 8 (20) : 5345 - 5345
  • [9] Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    Wang, Michael
    Fayad, Luis
    Wagner-Bartak, Nicolaus
    Zhang, Liang
    Hagemeister, Fredrick
    Neelapu, Sattva S.
    Samaniego, Felipe
    McLaughlin, Peter
    Fanale, Michelle
    Younes, Anas
    Cabanillas, Fernando
    Fowler, Nathan
    Newberry, Kate J.
    Sun, Luhong
    Young, Ken H.
    Champlin, Richard
    Kwak, Larry
    Feng, Lei
    Badillo, Maria
    Bejarano, Maria
    Hartig, Kimberly
    Chen, Wendy
    Chen, Yiming
    Byrne, Catriona
    Bell, Neda
    Zeldis, Jerome
    Romaguera, Jorge
    LANCET ONCOLOGY, 2012, 13 (07): : 716 - 723
  • [10] A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).
    Morrison, V. A.
    Jung, S.
    Johnson, J. L.
    Leonard, J.
    Cheson, B. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345